Immunology and Microbiology
Vaccination Policy
100%
COVID-19
74%
Vaccine Efficacy
68%
Immunogenicity
49%
Severe Acute Respiratory Syndrome Coronavirus 2
33%
Primary Immunodeficiency
33%
Neutralizing Antibody
27%
T Cell
25%
Common Variable Immunodeficiency
25%
Omicron Coronavirus Variant
24%
Immune Response
23%
Hepatitis B Vaccination
16%
Hepatitis A
16%
Hepatitis Virus
16%
Monkeypox Virus
16%
Vaccinium
16%
Neutralization
12%
Binding Antibody
11%
Antibody Response
11%
Smallpox Vaccine
11%
Humoral Immune Deficiency
10%
Spike
9%
Hepatitis B Virus
9%
Phagocyte
8%
Lineages
8%
Yellow Fever
8%
Dengue Fever
8%
Hemorrhagic Fever
8%
Monkeypox
8%
Antibody Titer
7%
Immunodeficiency
7%
B Cell
7%
Immunoglobulin G Antibody
6%
Breakthrough Infection
6%
X-Linked Agammaglobulinemia
6%
Immunosuppressive Drug
5%
Humoral Immunity
5%
Adoptive Immunity
5%
Medicine and Dentistry
Severe Acute Respiratory Syndrome Coronavirus 2
29%
COVID-19
19%
Infection
19%
Medical Student
16%
Health Care
16%
Randomized Controlled Trial
16%
Omicron Coronavirus Variant
16%
Hepatitis B Vaccination
16%
Antivirus Agent
16%
Immunogenicity
16%
Hepatitis B Virus
16%
Hepatitis Virus
16%
Hepatitis A
16%
Cohort Effect
16%
Outpatient
8%
Chronic Lung Disease
8%
Diseases
8%
Yellow Fever
8%
COVID-19 Vaccination
7%
Immunoglobulin G Antibody
7%
Vitronectin
6%
Pharmacology, Toxicology and Pharmaceutical Science
Vaccination Policy
39%
SARS Coronavirus
27%
Virus Hepatitis
16%
Immunogenicity
16%
Randomized Controlled Trial
16%
Hepatitis B
16%
Hepatitis A
16%
Infection
15%
Antivirus Agent
13%
Hepatitis B Virus
9%
Yellow Fever
8%
Dengue
8%
Disease
8%
Immunoglobulin G Antibody
6%
Chronic Lung Disease
6%
Vitronectin
5%
